Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02617095

Enrollment

Registered

2015-11-30

Start date

2015-02-28

Completion date

2016-10-31

Last updated

2017-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndrome

Brief summary

The purpose of this study is to compare the efficacy and safety of T2762 versus Optive® in the treatment of moderate to severe Dry Eye Syndrome.

Interventions

DEVICEOptive

One drop in each eye 3 to 6 times daily

DEVICET2762

One drop in each eye 3 to 6 times daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Signed and dated informed consent. * Male or female aged ≥ 18 years old. * Diagnosis of moderate to severe dry eye syndrome

Exclusion criteria

* Pregnancy, lactation. * Childbearing potential woman who is not using a reliable method of contraception and is not surgically sterilised. * Inability of patient to understand the study procedures and thus inability to give informed consent. * Non-compliant patient * Participation in another clinical study at the same time as the present study. * Participation to the present study during the exclusion period of another clinical study. * Already included once in this study. * Ward of court. * Patient not covered by government health care scheme

Design outcomes

Primary

Measure	Time frame
Change of the symptomatology evaluation on a Visual Analogic Scale	Day 28

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026